Activation of the JAK-STAT signaling pathway inhibits cytotoxic T lymphocytes and counteracts the antitumor effects of anti-PD-1 immunotherapy in pancreatic cancer (60). This evidence concerns the gene PDCD1 and pancreatic neoplasm.